Dengue virus: pathogenesis and potential for small molecule inhibitors
Bioscience Reports · 28.08.2024 · 44 (8)
DOI: 10.1042/bsr20240134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioscience Reports, online erschienen am 14.08.2024. Verfasst von Navya Chauhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India. Hauptthemen laut MEDLINE: Dengue Virus, Antiviral Agents, Dengue. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India (DBT).
Abstract (Originalsprache)
Dengue, caused by dengue virus (DENV), is now endemic in nearly 100 countries and infection incidence is reported in another 30 countries. Yearly an estimated 400 million cases and 2200 deaths are reported. Effective vaccines against DENV are limited and there has been significant focus on the development of effective antiviral against the disease. The World Health Organization has initiated research programs to prioritize the development and optimization of antiviral agents against several viruses including Flaviviridae. A significant effort has been taken by the researchers to develop effective antivirals against DENV. Several potential small-molecule inhibitors like efavirenz, tipranavir and dasabuvir have been tested against envelope and non-structural proteins of DENV, and are in clinical trials around the world. We recently developed one small molecule, namely 7D, targeting the host PF4-CXCR3 axis. 7D inhibited all 4 serotypes of DENV in vitro and specifically DENV2 infection in two different mice models. Although the development of dengue vaccines remains a high priority, antibody cross reactivity among the serotypes and resulting antibody-dependent enhancement (ADE) of infection are major concerns that have limited the development of effective vaccine against DENV. Therefore, there has been a significant emphasis on the development of antiviral drugs against dengue. This review article describes the rescue effects of some of the small molecule inhibitors to viral/host factors associated with DENV pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India.
ORCID-Profile: Prasenjit Guchhait
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India (DBT)
Zitieren
APA
Chauhan, N., Gaur, K. K., Asuru, T. R., & Guchhait, P. (2024). Dengue virus: pathogenesis and potential for small molecule inhibitors. Bioscience Reports, 44(8). https://doi.org/10.1042/bsr20240134
Vancouver
Chauhan N, Gaur KK, Asuru TR, Guchhait P. Dengue virus: pathogenesis and potential for small molecule inhibitors. Bioscience Reports. 2024;44(8). doi:10.1042/bsr20240134
BibTeX
@article{Chauhan2024,
author = {Chauhan, Navya and Gaur, Kishan Kumar and Asuru, Tejeswara Rao and Guchhait, Prasenjit},
title = {Dengue virus: pathogenesis and potential for small molecule inhibitors},
journal = {Bioscience Reports},
year = {2024},
volume = {44},
number = {8},
doi = {10.1042/bsr20240134}
}
EUVIMED